
## James L Boyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6682767/publications.pdf Version: 2024-02-01



IAMES L ROVER

#	Article	IF	CITATIONS
1	Bile Salt Transporters: Molecular Characterization, Function, and Regulation. Physiological Reviews, 2003, 83, 633-671.	28.8	873
2	Molecular Pathogenesis of Cholestasis. New England Journal of Medicine, 1998, 339, 1217-1227.	27.0	719
3	Bile Formation and Secretion. , 2013, 3, 1035-1078.		605
4	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 394-419.	7.3	507
5	The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis. New England Journal of Medicine, 1983, 308, 1-7.	27.0	430
6	Mechanisms and regulation of bile secretion. Hepatology, 1991, 14, 551-566.	7.3	398
7	OSTα-OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology, 2005, 42, 1270-1279.	7.3	315
8	Drug-induced cholestasis. Hepatology, 2011, 53, 1377-1387.	7.3	305
9	Cellular localization and up-regulation of multidrug resistance–associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology, 2001, 33, 783-791.	7.3	261
10	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents. American Journal of Physiology - Renal Physiology, 2006, 290, G1124-G1130.	3.4	255
11	Pattern of Necrosis in Acute Viral Hepatitis. New England Journal of Medicine, 1970, 283, 1063-1071.	27.0	254
12	Fibrates and cholestasis. Hepatology, 2015, 62, 635-643.	7.3	244
13	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology, 2000, 118, 163-172.	1.3	240
14	Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science, 2015, 347, 1253-1256.	12.6	229
15	Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications. Hepatology, 1998, 28, 1449-1453.	7.3	203
16	Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight, 2017, 2, e90780.	5.0	181
17	Mechanisms of bile acid mediated inflammation in the liver. Molecular Aspects of Medicine, 2017, 56, 45-53.	6.4	174
18	Mrp4â^'/â^' mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology, 2006, 43, 1013-1021.	7.3	164

#	Article	IF	CITATIONS
19	Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. Journal of Hepatology, 2004, 40, 585-591.	3.7	161
20	Functional Complementation between a Novel Mammalian Polygenic Transport Complex and an Evolutionarily Ancient Organic Solute Transporter, OSTα-OSTβ. Journal of Biological Chemistry, 2003, 278, 27473-27482.	3.4	157
21	Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. Journal of Hepatology, 1994, 20, 707-713.	3.7	150
22	Isolated rat hepatocyte couplets in short-term culture: Structural characteristics and plasma membrane reorganization. Hepatology, 1987, 7, 216-223.	7.3	149
23	Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology, 2001, 121, 1473-1484.	1.3	149
24	Molecular regulation of hepatocellular transport systems in cholestasis. Journal of Hepatology, 1999, 31, 165-178.	3.7	148
25	Tumor Necrosis Factor α-dependent Up-regulation of Lrh-1 and Mrp3(Abcc3) Reduces Liver Injury in Obstructive Cholestasis. Journal of Biological Chemistry, 2003, 278, 36688-36698.	3.4	136
26	Canalicular Bile Secretion in Man STUDIES UTILIZING THE BILIARY CLEARANCE OF [14C]MANNITOL. Journal of Clinical Investigation, 1974, 54, 773-781.	8.2	128
27	The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. Journal of Clinical Investigation, 2002, 110, 965-972.	8.2	124
28	Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology, 1993, 104, 604-612.	1.3	120
29	Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology, 2005, 42, 1184-1193.	7.3	112
30	Molecular Alterations in Hepatocyte Transport Mechanisms in Acquired Cholestatic Liver Disorders. Seminars in Liver Disease, 2000, Volume 20, 373-384.	3.6	111
31	Mechanisms of Hepatic Transport of Drugs: Implications for Cholestatic Drug Reactions. Seminars in Liver Disease, 2002, 22, 123-136.	3.6	109
32	Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. Gastroenterology, 1995, 109, 1600-1611.	1.3	106
33	Canalicular Bile flow and Bile Secretory Pressure. Gastroenterology, 1970, 59, 853-859.	1.3	101
34	ATP8B1 Deficiency Disrupts the Bile Canalicular Membrane Bilayer Structure in Hepatocytes, But FXR Expression and Activity Are Maintained. Gastroenterology, 2009, 136, 1060-1069.e4.	1.3	98
35	Radixin Is Required to Maintain Apical Canalicular Membrane Structure and Function in Rat Hepatocytes. Gastroenterology, 2006, 131, 878-884.	1.3	96
36	Taurocholate stimulates transcytotic vesicular pathways labeled by horseradish peroxidase in the isolated perfused rat liver. Gastroenterology, 1990, 99, 216-228.	1.3	94

#	Article	IF	CITATIONS
37	Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. American Journal of Physiology - Cell Physiology, 2007, 293, C1709-C1716.	4.6	90
38	OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Frontiers in Bioscience - Landmark, 2009, Volume, 2829.	3.0	90
39	Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology, 2011, 53, 548-557.	7.3	90
40	The Bile Salt Export Pump: Clinical and Experimental Aspects of Genetic and Acquired Cholestatic Liver Disease. Seminars in Liver Disease, 2010, 30, 125-133.	3.6	87
41	The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology, 2014, 59, 580-591.	7.3	86
42	Tight Junctions in Normal and Cholestatic Liver: Does the Paracellular Pathway Have Functional Significance?. Hepatology, 1983, 3, 614-617.	7.3	80
43	Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology, 2002, 36, 49-54.	7.3	78
44	Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. American Journal of Physiology - Renal Physiology, 2010, 299, G126-G135.	3.4	78
45	Organ-specific alterations in RARα:RXRα abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology, 2002, 123, 599-607.	1.3	76
46	New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically. Journal of Hepatology, 2007, 46, 365-371.	3.7	76
47	Effects of Ca2+ agonists on cytosolic Ca2+ in isolated hepatocytes and on bile secretion in the isolated perfused rat liver. Hepatology, 1992, 15, 107-116.	7.3	73
48	Taurolithocholic Acid Exerts Cholestatic Effects via Phosphatidylinositol 3-Kinase-dependent Mechanisms in Perfused Rat Livers and Rat Hepatocyte Couplets. Journal of Biological Chemistry, 2003, 278, 17810-17818.	3.4	73
49	Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. Journal of Lipid Research, 2010, 51, 2265-2274.	4.2	73
50	Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes. Hepatology, 1999, 29, 477-482.	7.3	72
51	Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signali. Hepatology, 2012, 55, 1485-1494.	7.3	71
52	Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology, 2014, 59, 1030-1042.	7.3	71
53	Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. Hepatology, 2008, 48, 1558-1569.	7.3	70
54	Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease?. Gastroenterology, 2005, 129, 735-740.	1.3	69

#	Article	IF	CITATIONS
55	Mouse organic solute transporter α deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology, 2010, 51, 181-190.	7.3	69
56	[34] Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods in Enzymology, 1990, 192, 534-545.	1.0	68
57	Hepatic toxicity of Vitamin A and synthetic retinoids. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 334-342.	2.8	68
58	Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. Hepatology, 2009, 50, 1588-1596.	7.3	66
59	Protein kinase C agonists inhibit bile secretion independently of effects on the microcirculation in the isolated perfused rat liver. Hepatology, 1989, 10, 8-13.	7.3	65
60	Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology, 2004, 39, 1382-1389.	7.3	64
61	Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology, 1999, 117, 420-428.	1.3	63
62	Clinicopathology conferences: Inflammation-induced cholestasis. Hepatology, 1998, 28, 253-260.	7.3	61
63	Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations. Molecular Aspects of Medicine, 2014, 37, 3-14.	6.4	60
64	Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. American Journal of Physiology - Renal Physiology, 2001, 281, G316-G322.	3.4	59
65	Organic Solute Transporter, OSTα-OSTβ: Its Role in Bile Acid Transport and Cholestasis. Seminars in Liver Disease, 2010, 30, 178-185.	3.6	57
66	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	4.4	57
67	Effect of Albumin Binding on Extraction of Sulfobromophthalein by Perfused Elasmobranch Liver: Evidence for Dissociation-Limited Uptake. Hepatology, 1984, 4, 492-501.	7.3	56
68	Bileâ€Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology, 2019, 70, 871-882.	7.3	56
69	Outcome of COVIDâ€19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology, 2021, 73, 2099-2109.	7.3	56
70	The effect of changes in the fluid state of rat liver plasma membrane on the transport of taurocholate. Hepatology, 1987, 7, 61-66.	7.3	54
71	Role of sodium/hydrogen exchanger isoform NHE3 in fluid secretion and absorption in mouse and rat cholangiocytes. American Journal of Physiology - Renal Physiology, 2001, 280, G247-G254.	3.4	52
72	Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid–fed mouse model of cholestasis. Hepatology, 2016, 64, 2151-2164.	7.3	52

#	Article	IF	CITATIONS
73	A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study. Hepatology, 1982, 2, 187S-201S.	7.3	51
74	NHERF-1 Binds to Mrp2 and Regulates Hepatic Mrp2 Expression and Function. Journal of Biological Chemistry, 2010, 285, 19299-19307.	3.4	51
75	A Positive Feedback Loop of TET3 and TGF-β1 Promotes Liver Fibrosis. Cell Reports, 2020, 30, 1310-1318.e5.	6.4	50
76	<i>THIOBACILLUS NOVELLUS</i> . Journal of Bacteriology, 1959, 78, 197-202.	2.2	50
77	The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. Journal of Clinical Investigation, 2002, 110, 965-972.	8.2	50
78	FXR: a target for cholestatic syndromes?. Expert Opinion on Therapeutic Targets, 2006, 10, 409-421.	3.4	49
79	The use of isolated rat hepatocyte couplets in hepatobiliary physiology. Journal of Hepatology, 1990, 10, 387-394.	3.7	48
80	Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. American Journal of Physiology - Renal Physiology, 2012, 302, G925-G936.	3.4	48
81	Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. Journal of Hepatology, 2015, 63, 1440-1448.	3.7	48
82	Biochemical Separation of Na+, K+-ATPase from a "Purified―Light Density, "Canalicular―Enriched Plasma Membrane Fraction from Rat Liver. Hepatology, 2007, 3, 18-28.	7.3	47
83	Sodium Taurocholate Modifies the Bile Acid-Independent Fraction of Canalicular Bile Flow in the Rhesus Monkey. Journal of Clinical Investigation, 1979, 64, 312-320.	8.2	45
84	Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. Journal of Hepatology, 2014, 60, 160-166.	3.7	44
85	Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology, 2018, 82, 51-60.	2.0	43
86	Molecular identification and functional characterization of Mdr1a in rat cholangiocytes. Gastroenterology, 2000, 119, 1113-1122.	1.3	41
87	Down-regulation of the Na + /taurocholate cotransporting polypeptide during pregnancy in the rat. Journal of Hepatology, 2003, 38, 148-155.	3.7	39
88	The farnesoid X receptor FXRα/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1400-R1409.	1.8	39
89	Canalicular Export Pumps Traffic with Polymeric Immunoglobulin A Receptor on the Same Microtubule-associated Vesicle in Rat Liver. Journal of Biological Chemistry, 1999, 274, 26416-26424.	3.4	38
90	Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 2017, 51, e11-e16.	2.2	38

#	Article	IF	CITATIONS
91	Effects of protein kinase C and cytosolic Ca2+ on exocytosis in the isolated perfused rat liver. Hepatology, 1994, 20, 1032-1040.	7.3	37
92	Regulation of intracellular pH in the hepatocyte. Journal of Hepatology, 1996, 24, 631-644.	3.7	37
93	Unimpaired osmotic water permeability and fluid secretion in bile duct epithelia of AQP1 null mice. American Journal of Physiology - Renal Physiology, 2002, 283, G739-G746.	3.4	37
94	Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct–Ligated Mouse. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 679-688.	4.5	36
95	Role of Breast Cancer Resistance Protein in the Adaptive Response to Cholestasis. Drug Metabolism and Disposition, 2010, 38, 1673-1678.	3.3	35
96	Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion. Hepatology, 2013, 57, 2418-2426.	7.3	35
97	Cenicriviroc, a cytokine receptor antagonist, potentiates allâ€ŧrans retinoic acid in reducing liver injury in cholestatic rodents. Liver International, 2018, 38, 1128-1138.	3.9	35
98	The role of bile acids in cholestatic liver injury. Annals of Translational Medicine, 2021, 9, 737-737.	1.7	34
99	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1012-1013.	7.3	34
100	[33] Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods in Enzymology, 1990, 192, 517-533.	1.0	33
101	All- <i>Trans</i> -Retinoic Acid Improves Cholestasis in <i>α</i> -Naphthylisothiocyanate–Treated Rats and <i>Mdr2</i> <sup>â^'/â^'</sup> Mice. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 94-98.	2.5	33
102	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. Hepatology, 2007, 3, 209-220.	7.3	32
103	Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come. Hepatology, 2013, 57, 1691-1693.	7.3	31
104	Mechanisms of Bile Secretion and Hepatic Transport. , 1986, , 609-636.		31
105	The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage. Digestive Diseases, 2017, 35, 232-234.	1.9	30
106	Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology, 2018, 155, 1578-1592.e16.	1.3	30
107	The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166085.	3.8	30
108	Mechanisms and regulation of bile secretion. Hepatology, 1991, 14, 551-566.	7.3	29

James L Boyer

#	Article	IF	CITATIONS
109	Nuclear receptors RXRα:RARα are repressors for human MRP3 expression. American Journal of Physiology - Renal Physiology, 2007, 292, G1221-G1227.	3.4	28
110	A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis. Hepatology, 2012, 55, 1901-1911.	7.3	28
111	Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology and Therapeutics, 2020, 108, 1213-1223.	4.7	28
112	Nitric oxide and guanosine 3?,5?-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. Hepatology, 1998, 28, 1621-1628.	7.3	27
113	Induction of Murine Hepatocyte Death by Membrane-Bound CD95 (Fas/APO-1)-Ligand: Characterization of an In Vitro System. Hepatology, 2000, 32, 779-785.	7.3	27
114	Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis. Journal of Hepatology, 2021, 74, 550-559.	3.7	27
115	Structural heterogeneity of hepatocyte "tight―junctions: A quantitative analysis. Hepatology, 1981, 1, 193-203.	7.3	26
116	A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases and Sciences, 2016, 61, 3506-3512.	2.3	26
117	ATP-dependent GSH and glutathione <i>S</i> -conjugate transport in skate liver: role of an Mrp functional homologue. American Journal of Physiology - Renal Physiology, 2000, 279, G417-G425.	3.4	25
118	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology, 1999, 30, 602-605.	7.3	24
119	Bile salt excretion in skate liver is mediated by a functional analog of Bsep/Spgp, the bile salt export pump. American Journal of Physiology - Renal Physiology, 2000, 278, G57-G63.	3.4	24
120	Isolation of functional polarized bile duct units from mouse liver. American Journal of Physiology - Renal Physiology, 2001, 280, G241-G246.	3.4	23
121	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na+/Taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. Hepatology, 1998, 28, 789-795.	7.3	22
122	Hepatic sequestration and modulation of the canalicular transport of the organic cation, daunorubicin, in the rat. Hepatology, 1999, 29, 483-493.	7.3	21
123	Characterization of ion transport mechanisms involved in bombesin-stimulated biliary secretion in rat cholangiocytes. Journal of Hepatology, 1999, 30, 1045-1051.	3.7	21
124	Ostα depletion protects liver from oral bile acid load. American Journal of Physiology - Renal Physiology, 2011, 301, G574-G579.	3.4	21
125	Altered expression and function of canalicular transporters during early development of cholestatic liver injury in <i>Abcb4-</i> deficient mice. American Journal of Physiology - Renal Physiology, 2014, 306, G670-G676.	3.4	20
126	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology and Hepatology, 2018, 16, 591-593.	4.4	20

#	Article	IF	CITATIONS
127	HEPATIC AND EXTRAHEPATIC SYNTHESIS AND DISPOSITION OF DINITROPHENYL- <i>S</i> -GLUTATHIONE IN BILE DUCT-LIGATED RATS. Drug Metabolism and Disposition, 2006, 34, 1301-1309.	3.3	19
128	Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea. Hepatology, 2020, 71, 1879-1882.	7.3	19
129	Cryptic na+, k+-atpase activity in rat liver canalicular plasma membranes: Evidence for its basolateral origin. Hepatology, 1990, 11, 223-229.	7.3	18
130	Cl <sup>â^'</sup> -dependent secretory mechanisms in isolated rat bile duct epithelial units. American Journal of Physiology - Renal Physiology, 2001, 281, G438-G446.	3.4	18
131	Na+/H+ exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. Hepatology, 2015, 62, 1227-1236.	7.3	18
132	Selective Hepatic Uptake and Biliary Excretion of 35S-Sulfobromophthalein in Marine Elasmobranchs. Gastroenterology, 1976, 70, 254-256.	1.3	17
133	Cytoskeletal organization in clusters of isolated polarized skate hepatocytes: Structural and functional evidence for microtubule-dependent transcytosis. The Journal of Experimental Zoology, 1995, 271, 273-284.	1.4	17
134	Primary Biliary Cirrhosis. Hepatology, 1984, 4, 29S-32S.	7.3	16
135	N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. BMC Cell Biology, 2008, 9, 57.	3.0	16
136	Papaverine inhibits transcytotic vesicle transport and lipid excretion into bile in isolated perfused rat liver. Hepatology, 1992, 16, 1036-1042.	7.3	15
137	Enterohepatic circulation of scymnol sulfate in an elasmobranch, the little skate ( <i>Raja) Tj ETQq1 1 0.784314</i>	rgBT /Ove 3.4	rlock 10 Tf 5
138	Cholestatic syndromes. Current Opinion in Gastroenterology, 2003, 19, 216-231.	2.3	13
139	Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods in Molecular Biology, 2019, 1981, 363-372.	0.9	13
140	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2020, 15, 1-2.	2.1	13
141	Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. American Journal of Physiology - Renal Physiology, 2004, 286, G762-G768.	3.4	12
142	H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4α+ Periportal Hepatocytes but Not Cytokeratin 19+ Cholangiocytes in Cholestatic Livers. Hepatology Communications, 2018, 2, 1356-1368.	4.3	12
143	ATP regulation of a swelling-activated osmolyte channel in skate hepatocytes. , 1997, 279, 471-475.		11
144	Advancing the bile-ology of cholestatic liver disease. Hepatology, 2001, 33, 758-759.	7.3	10

#	Article	IF	CITATIONS
145	It's all about bile. Hepatology, 2009, 49, 711-723.	7.3	10
146	Adjunct Fenofibrate Upâ€regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. Hepatology Communications, 2021, 5, 2035-2051.	4.3	10
147	Hepatic metabolism of 1-14C octanoic and 1-14C margaric acids. Lipids, 1969, 4, 615-617.	1.7	9
148	A homozygous R148W mutation in <i>Semaphorin 7A</i> causes progressive familial intrahepatic cholestasis. EMBO Molecular Medicine, 2021, 13, e14563.	6.9	9
149	A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization. PLoS ONE, 2016, 11, e0158269.	2.5	8
150	Sperber I. Secretion of organic anions in the formation of urine and bile[Pharmacol. Rev. 1959;11:109–134]. Journal of Hepatology, 2002, 36, 4-7.	3.7	7
151	The Hepatobiliary Paracellular Pathway: A Paradigm Revisited. Gastroenterology, 2014, 147, 965-968.	1.3	7
152	A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World Journal of Gastroenterology, 2006, 12, 2536.	3.3	7
153	Cholestatic syndromes. Current Opinion in Gastroenterology, 2002, 18, 314-329.	2.3	6
154	Bile canalicular secretion – tales from Vienna and Yale. Wiener Medizinische Wochenschrift, 2008, 158, 534-538.	1.1	6
155	Now you see it, now you don't. Hepatology, 2013, 58, 446-447.	7.3	6
156	Bile Infarcts: New Insights Into the Pathogenesis of Obstructive Cholestasis. Hepatology, 2019, 69, 473-475.	7.3	6
157	OSTα-OSTβ Guards the Ileal Enterocyte From the Accumulation of Toxic Levels of Bile Acids. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 649-650.	4.5	4
158	Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflammation and Cell Signaling, 2017, 4, .	1.6	4
159	Na <sup>+</sup> -taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate <i>Leucoraja erinacea</i> is not a physiological bile salt transporter. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R477-R484.	1.8	3
160	Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports, 2022, 4, 100450.	4.9	3
161	Cholestasis: Genetic and Acquired. Seminars in Liver Disease, 2010, 30, 113-115.	3.6	2
162	The origins of hepatobiliary and gastrointestinal physiology. Hepatology, 2015, 61, 1452-1454.	7.3	2

James L Boyer

#	Article	IF	CITATIONS
163	CFTR-associated ligand is a negative regulator of Mrp2 expression. American Journal of Physiology - Cell Physiology, 2017, 312, C40-C46.	4.6	2
164	Mechanisms of Bile Formation: An Introduction. , 2004, , 1-8.		2
165	Small-duct sclerosing cholangitis associated with Schistosoma mansoni. Hepatology, 2011, 53, 712-713.	7.3	1
166	Maintaining a Vibrant and Productive Laboratory as a Senior Investigator. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 299-300.	4.5	1
167	Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic. Journal of Hepatology, 2019, 71, 657-659.	3.7	1
168	Letter to the Editor: On the mechanisms of biliary flux. Hepatology, 2022, 75, 492-493.	7.3	1
169	Treatment of chronic cholestasis: What we know and what we will know?. Clinical Liver Disease, 2016, 8, 140-144.	2.1	0
170	Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars in Liver Disease, 2021, 41, 206-212.	3.6	0
171	Paul David Berk, editor extraordinaire and bilirubinologist. Hepatology, 2022, 75, 236-237.	7.3	0
172	Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis. FASEB Journal, 2008, 22, 796.1.	0.5	0